89bio, Inc. (ETNB) Reports Second-Quarter Results; Leerink Partners and Citi Maintain ‘Buy’ Ratings
On August 7, 2025, 89bio, Inc. (NASDAQ:ETNB) reported its Q2 2025 results.
89Bio Inc. (ETNB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 19,889,683 | $195,316,687 | 3.29% | |
| 2. | Suvretta Capital Management Aaron Cowen | 14,210,000 | $139,542,200 | -1% | 4.21% |
| 3. | Deep Track Capital David Kroin | 9,500,000 | $93,290,000 | +2% | 2.99% |
| 4. | VenBio Select Advisor Kurt Von Emster | 6,750,000 | $66,285,000 | +7% | 1.16% |
| 5. | Citadel Investment Group Ken Griffin | 3,836,892 | $37,678,279 | -25% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.75 | 5,714,285 | $49,999,993.75 | 19,554,319 | 2025-01-30 | Filing | |
| $6.71 | 10,000 | $67,100.00 | 25,000 | 2025-01-22 | Filing | |
| $6.55 | 5,000 | $32,750.00 | 15,000 | 2025-01-21 | Filing | |
| $7.89 | 5,000 | $39,450.00 | 471,236 | 2024-12-06 | Filing | |
| $8.00 | 10,000 | $80,000.00 | 10,000 | 2024-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.02 | 10,461 | $115,280.22 | 309,364 | 2025-07-15 | Filing | |
| $5.95 | 15,329 | $91,207.55 | 328,323 | 2025-04-15 | Filing | |
| $6.49 | 10,963 | $71,149.87 | 271,833 | 2025-01-15 | Filing | |
| $8.12 | 27,955 | $226,994.60 | 187,796 | 2024-10-30 | Filing | |
| $10.91 | 52,718 | $575,153.38 | 459,171 | 2024-04-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,788,363 | $204,191,519 | 0.1% | |
| 2. | 10,569,424 | $103,791,745 | 0% | |
| 3. | 8,242,154 | $80,937,952 | 0% | |
| 4. | 4,249,957 | $41,734,578 | 0% | |
| 5. | 4,035,390 | $39,627,530 | 0.04% |
News See All
11 Best Single Digit Stocks to Buy According to Hedge Funds
The winning streak of U.S. stocks extended on Wednesday, August 13, 2025, with the S&P 500 and Nasdaq reaching fresh record highs for the second day in a row.
10 Best Low Priced Biotech Stocks to Buy Now
On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations...
10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance.
13 Best Biotech Stocks To Buy Under $20
In this article, we're going to take a look at 13 best biotech stocks to buy under $20.
5 Stocks Insiders are Buying Now
Satellite communication and internet services company EchoStar Corp (NASDAQ:SATS) ranks fifth in our list of the stocks with the highest insider purchasing activity recently.
11 Best Small-Cap Growth Stocks to Invest In
In this piece, we will take a look at the 11 best small-cap growth stocks to invest in.
15 Most Shorted Stocks That Are Loved By Analysts
In this piece, we will take a look at the 15 most shorted stocks that are loved by analysts.
Analysts Are Increasing Price Targets of These 5 Stocks
In this article, we discuss the 5 stocks receiving price-target hike from analysts.
Hedge Fund and Insider Trading News: Hestia Capital Management, Tiger Global Management, Rockefeller Capital Management, Farallon Capital Management, Odey Asset Management, Rokos Capital Management, Excalibur Fixed Income Fund, Xos Inc (XOS), 89bio, Inc. (ETNB), and More
Tiger Global Management founder Chase Coleman, whose firm was stung by last year’s tech rout, said the sector now looks attractive thanks to artificial intelligence and other new technologies.
Billionaire Hedge Funds
